Marshall Financial Group LLC Sells 1,936 Shares of IDEXX Laboratories, Inc. $IDXX

Marshall Financial Group LLC decreased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 80.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 483 shares of the company’s stock after selling 1,936 shares during the quarter. Marshall Financial Group LLC’s holdings in IDEXX Laboratories were worth $327,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its stake in shares of IDEXX Laboratories by 2.5% in the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after acquiring an additional 15 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in shares of IDEXX Laboratories by 4.4% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after purchasing an additional 16 shares during the last quarter. Moss Adams Wealth Advisors LLC boosted its stake in IDEXX Laboratories by 3.3% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock worth $337,000 after purchasing an additional 17 shares in the last quarter. CWA Asset Management Group LLC boosted its stake in IDEXX Laboratories by 3.5% in the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock worth $344,000 after purchasing an additional 17 shares in the last quarter. Finally, Private Trust Co. NA grew its position in IDEXX Laboratories by 9.4% during the 3rd quarter. Private Trust Co. NA now owns 209 shares of the company’s stock valued at $134,000 after purchasing an additional 18 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Barclays reduced their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Piper Sandler cut their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. BTIG Research decreased their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Finally, Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $783.33.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 1,464 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the transaction, the director owned 648 shares of the company’s stock, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the sale, the executive vice president owned 9,823 shares of the company’s stock, valued at $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 45,957 shares of company stock worth $29,862,109. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Performance

IDXX stock opened at $578.51 on Tuesday. The company has a market cap of $46.00 billion, a P/E ratio of 44.26, a price-to-earnings-growth ratio of 3.50 and a beta of 1.66. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The stock’s fifty day moving average price is $642.81 and its 200-day moving average price is $664.28.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the company posted $2.53 EPS. The firm’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.